FHD-286

Foghorn Therapeutics Inc. · Phase 1 active Small molecule

At a glance

Generic name	FHD-286
Sponsor	Foghorn Therapeutics Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia (PHASE1)
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies (PHASE1)
FHD-286 in Subjects With Metastatic Uveal Melanoma (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

FHD-286 CI brief — competitive landscape report
FHD-286 updates RSS · CI watch RSS
Foghorn Therapeutics Inc. portfolio CI